This is a challenging question. Traditionally patients with immune mediated or autoimmune illnesses were excluded from PD1 or PDL1 inhibitor clinical trials. There is some retrospective data emerging in NSCLC and in melanoma that some patients with autoimmune conditions could be safely treated with ...